dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Pöördumine

Sotsiaalministeerium · 21. september 2020
Viit
1.4-2/2746-1
Registreeritud
21. september 2020
Dokumendi liik
Sissetulev kiri
Adressaat
K. W.
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2020
Vastutaja
Elen Ohov (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Euroopa Liidu ja väliskoostöö osakond)
Lahendamise tähtaeg
15. september 2020

Failid

  • 📎Kaaskiri.pdf128 KB
  • 📎Letter ESI_enc.pdf54 KB
  • 📎Letter ESI.pdf292 KB

Sisu (failidest)

Enclosures Page 1 of 1 Bonn/Brussels, 10 September 2020 Dear Ministers, The COVID-19-pandemic is inflicting huge human and economic costs on the Euro- pean Union (EU) and the world. As you know, a permanent solution to this crisis is most likely to be brought about by the development and deployment of an effective and safe vac- cine against the virus. The scale of the crisis means that time pressure is unprecedented. We have to invest up-front in vaccine development to ensure that successful and safe vaccines are being pro- duced at the scale required as early as possible. This is why the Commission adopted an EU Strategy for COVID-19 vaccines and decided to finance a part of the upfront costs faced by vaccines producers from the Emergency Support Instrument (“ESI”). You have all endorsed this Strategy, and this swift and unified action by the European Commission representing the EU Member States will ensure sufficient and quick delivery of a safe and effective vaccine. In order to maximise the chances of success, the most promising candidates should be supported in their development and in the building-up of manufacturing capacity. Our common goal is to obtain a broad portfolio of vaccine candidates that contain dif- ferent technological approaches to achieve the highest possible chances of a successful vac- cine against COVID-19. During the virtual meeting of EU Health Ministers on 4 September 2020, a large ma- jority of you supported the idea of a broad portfolio, which would improve our chances of having access to a safe and effective vaccine as soon as possible. Page 2 of 2 As you all know, exploratory talks have been concluded with six manufacturers of po- tential vaccines and the first Advanced Purchase Agreement (APA) has been already signed with AstraZeneca, securing our access to what will probably be the first vaccine against COVID-19. In addition, negotiations are currently underway with other manufacturers. However, for the next steps funding has become a key issue, as the availability of funds from the EU Budget within ESI has been exhausted. As envisaged by the EU Strategy for COVID-19 vaccines, the option of a top-up to the ESI to cover any financing gap for additional contracts is available. In case an ESI top-up of 750 million Euro is agreed as outlined in the informal meeting we could further diversify the portfolio and better hedge against risks. Please find attached an estimate of the budget impli- cations based on the gross national income and assuming a minimum of seven vaccines in the portfolio. During the abovementioned meeting of EU Health Ministers a majority of you made a concrete commitment to increase the ESI budget or indicated your willingness to contribute financially, subject to national procedures. Your additional contributions to the ESI would become external assigned revenue for the EU budget and they would be used for securing the financing of further APAs. Given the urgency, we look forward to receiving your reply on your commitment to top-up the ESI by 15 September 2020 to EC Vaccines ([email protected]). The time has come to put words into action and gather the additional funding that could ensure that additional promising vaccines are part of the EU portfolio to the benefit of all citizens in the twenty-seven Member States of the European Union. It is essential that we continue to coordinate and strengthen our efforts in a spirit of solidarity, therefore let us remain united on the portfolio structure and together deliver a last- ing and decisive solution to our citizens against COVID-19. Yours sincerely, STELLA KYRIAKIDES JENS SPAHN MEMBER OF THE EUROPEAN COMMISSION FEDERAL MINISTER HEALTH AND FOOD SAFETY MEMBER OF THE GERMAN PARLIAMENT Enc. Aili Petti Teema: FW: ESI letter Bundesminister Jens Spahn und EU-Kommissarin Stella Kyriakides Manused: Letter ESI_enc.pdf; Letter ESI.pdf Tähtsus: Kõrge From: Tairi Täht <[email protected]> Sent: Thursday, September 10, 2020 3:38 PM To: Maris Jesse <[email protected]>; Heli Laarmann <[email protected]>; Elen Ohov <[email protected]>; [email protected]; Marten Kokk <[email protected]>; Tanel Kiik <[email protected]>; Triin Uusberg <[email protected]> Cc: Katrin Juhandi <[email protected]>; Kristiina Tuisk (Riigikantselei) <[email protected]>; Rasmus Sinivee <[email protected]> Subject: FW: ESI letter Bundesminister Jens Spahn und EU-Kommissarin Stella Kyriakides Importance: High Tere Siin on PRES+KOM ühiskiri liikmesriikidele vaktsiini eelostulepinguteks vajaliku ESI top up teemal, mis saadeti ka pealinnadesse. Meie nõusolekut anda oma lisapanus palutakse hiljemalt 15.09 (järgmine teisipäev). Sain eesistujast aru, et see saab olema ainuke ametlikumas vormis dokument, mida meile esitatakse sel teemal. PRES viitab alla meilis, et kõik info otsustamiseks (portfelli teemal) on olemas Steering Boardis. Tervitades Tairi *** TÄHELEPANU *** See e-kiri (kaasa arvatud manused) on mõeldud ainult e-kirja adressaatidele ning võib sisaldada ametialaseks kasutamiseks ettenähtud teavet. Teavet ei tohi ilma saatja selgelt väljendatud loata edasi saata ega mistahes viisil kõrvalistele isikutele avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, palun teavitage sellest kohe saatjat ning kustutage e-kiri oma arvutist. *** ATTENTION *** This e-mail and its attachments may contain official information. If you are not the intended recipient, please notify the sender immediately, delete this e-mail and destroy any copies. Any dissemination or use of this information by a person other than the intended recipient is unauthorized and may be unlawful . From: Katharina Wunderlich <[email protected]> Sent: Thursday, September 10, 2020 12:23 PM To: [email protected]; Zlatimira Dobreva ([email protected]) <Zlatimira.Dobreva@bg- permrep.eu>; [email protected]; Tairi Täht <[email protected]>; Mustonen Pasi <[email protected]>; [email protected]; [email protected]; Aikaterini Damigou (a.damigou@rp- grece.be) <[email protected]>; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; Ewa Magdalena Piasecka ([email protected]) <[email protected]>; [email protected]; João Miguel Lança <[email protected]>; [email protected]; [email protected]; [email protected]; Teodor Zepic ([email protected]) <[email protected]>; [email protected]; [email protected]; [email protected]; [email protected]; [email protected] Cc: [email protected]; [email protected]; '[email protected]' <[email protected]>; 'SVENSSON Lars Erik' <[email protected]>; Aurélien Perez ([email protected]) <[email protected]>; CZARNECKA Agnieszka <[email protected]>; Marie Charlotte van Lamsweerde (marie- 1 [email protected]) <[email protected]>; DE ELERA Alvaro <[email protected]> Subject: ESI letter Bundesminister Jens Spahn und EU-Kommissarin Stella Kyriakides Importance: High Dear colleagues, please find attached the letter of Minister Spahn and Commissioner Kyriakides to your capitals regarding the ESI top up to finance further APA contracts for COVID-19 vaccines. And just to clarify the issue on the budget that was also raised by our budget colleagues: the transfer of ESI money (around 1,1 billion Euro) from 2021 to 2020 (DAB No. 8) is needed to finance the current portfolio of 6 vaccines candidates. The additional 750 million Euro is needed for possible extensions of the vaccine portfolio. The decision which and how many additional vaccine candidates to take on board is decided by member states in the Vaccines Steering Board. Thank you for forwarding the letter to the responsible persons in your capitals as well. Kind regards Katharina Katharina WUNDERLICH Referentin Gesundheitspolitik Ständige Vertretung der Bundesrepublik Deutschland bei der Europäischen Union Rue Jacques de Lalaing 8-14, 1040 Brüssel Telefon: +32 2 787 1303 Folgen Sie uns! @GermanyInTheEU: Mobil: +32 476 762 116 E-Mail: [email protected] 2
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel